摘要
目的 探讨三组疾病胸腹水凝血抑制物的水平及其鉴别诊断意义。方法 组织因子途径抑制物 (TFPI)、凝血酶调节蛋白 (TM )和蛋白C(PC)采用ELISA法测定抗原浓度 ,抗凝血酶Ⅲ(ATⅢ )和肝素辅因子Ⅱ (HCⅡ )采用发色底物法测定活性量。结果 结核病组胸腹水TFPI和PC水平分别为 (3 5 .2 5± 13 .61) μg/L和 (4 6.97%± 2 3 .64 % )、恶性肿瘤组分别为 (3 4.10± 14 .97) μg/L和 (3 7.13 %± 2 3 .19% ) ,明显高于肝硬化组的 (7.84± 5 .45 ) μg/L和 (7.90 %± 4.63 % ) (P <0 .0 1)。ATⅢ肝硬化组 (4 9.5 3 %± 2 4.14 % )明显高于结核病组 (3 1.44 %± 2 0 .72 % ) (P <0 .0 5 )。HCⅡ肝硬化组 (91.5 4%± 9.3 1% )和恶性肿瘤组 (88.80 %± 9.2 4% )均明显高于结核病组 (76.5 7%±11.12 % ) (P <0 .0 1)。恶性肿瘤组TM (5 5 .87± 3 7.16) μg/L高于结核病组 (3 6.76± 18.80 ) μg/L ,结核病组又高于肝硬化组 (12 .2 9± 8.5 2 ) μg/L(P <0 .0 1)。在恶性肿瘤组的 5项凝血抑制物指标中 ,TFPⅠ、ATⅢ和TM三项指标在胸腹水脱落细胞阳性组与阴性组间有明显差异 (P <0 .0 5 )。结论 联合检测多项凝血抑制物有助于不同胸腹水疾病的鉴别 。
Objective To study differential diagnosis significance and level of coagulative inhibitors in pleural and ascitic fluid with three diseases.Methods Tissue factor pathway inhibitor (TFPI ),thrombomodulin(TM)and protein C (PC)were measured by ELISA, antithrombin Ⅲ (ATⅢ)and heparin cofactor Ⅱ(HCⅡ) by colorimetric assay.Results The levels of TFPI and PC in pleural and ascitic fluid were marked higher in tuberculosis group(35.25±13.61)μg/L and (46.97%±23.64%) and malignant tumor group(34.10±14.97)μg/L and (37.13%±23.19%) than that in cirrhosis group(7.84±5.45)μg/L,(7.90%±4.63%)( P <0.01).The ATⅢ level in pleural and ascitic fluid were marked higher in cirrhosis group(49.53%±24.14%) than that in tuberculosis group(31.44%±20.72%)( P <0.05).The HCⅡ level in pleural and ascitic fluid were marked higher in cirrhosis group(91.54%± 9.31% )and malignant tumor group(88.80%±9.24%) than that in tuberculosis group(76.57%± 11.12% )( P <0.01).The level of TM in pleural and ascitic fluid were marked higher in malignant tumor group(55.87 ±37.16)μg/L than that in tuberculosis group (36.76±18.80)μg/L( P <0.01),and tuberculosis group than that in cirrhosis group(12.29±8.52)μg/L( P <0.01).Among five traget of coagulative inhibitors in malignant tumor group, the TFPI and ATⅢ and TM levels were significant difference between positive group in pleural and ascitic fluid with cancer cell and nagative group without cancer cell( P <0.05).Conclusions To join test with targets of coagulative inhibitors can help determine the quality of pleural and ascitic fluid, and can help understand between the coagulative inhibitors and pleural and ascitic fluid pathologic processes.
出处
《临床内科杂志》
CAS
北大核心
2002年第S1期71-73,共3页
Journal of Clinical Internal Medicine
关键词
胸水
腹水
凝血抑制
Pleural fluid
Ascitic fluid
Coagulative inhibitors
